



Supplementary Figure S1:



Supplementary Figure S1: Description of the SARS-CoV-2 pandemic in Aragón (Spain) and the placental samples collected in the timeframes indicated.

Supplementary Figure S2:



Supplementary Figure S2: A) SARS-CoV-2 variants. History of principal designated SARS-CoV-2 variants over time as designated by WHO (<https://www.who.int/activities/tracking-SARS-CoV-2-variants>) during preVOC (March-December 2020) and VOC era (January 2021-present). The period in which samples for this study were taken is indicated on the left. B) The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Aragón, Spain. Number of samples subjected to sequencing to identify the variant/lineage of SARS-CoV-2 by time period (January 2021-present) in our area. Note that the number of samples sequenced to identify the SARS-CoV-2 variant is not representative of the number of infections reported.

Supplementary Figure S3.



Supplementary Figure S3: Representation of coverage of the SARS-CoV-2 genome obtained by whole genome sequencing. Three representative images are shown.

FIRST DOSE		SECOND DOSE		SARS-CoV-2 INFECTION	
Trimester	Days after 1 ^o dose	Trimester	Days between last dose and SARS-CoV-2 diagnosis	SYN	PS
3 ^o	21	3 ^o	61	A	Omicron
Preconception	21	Preconception	59	A	Delta
1 ^o	-	-	142	A	Delta/Omicron
1 ^o	-	-	133	A	Delta/Omicron
1 ^o	21	1 ^o	235	M	Delta/Omicron
2 ^o	22	2 ^o	136	A	Delta/Omicron
1 ^o	21	1 ^o	159	M	Delta/Omicron
2 ^o	28	2 ^o	100	M	Delta/Omicron
Preconception	21	1 ^o	325	A	Omicron
2 ^o	-	-	131	A	Omicron
Preconception	-	-	135	M	Omicron
3 ^o	28	3 ^o	3	M	Omicron
Preconception	344	3 ^o	22	A	Omicron
3 ^o	-	-	28	M	Omicron
2 ^o	21	2 ^o	134	A	Omicron
Preconception*#	92	Preconception	7	A	Omicron
Preconception	21	Preconception	177	M	Omicron
Preconception	291	3 ^o	41	A	Omicron
Preconception	21	Preconception	181	M	Omicron
2 ^o	21	2 ^o	112	A	Omicron
2 ^o	28	2 ^o	104	A	Omicron
2 ^o	21	2 ^o	120	M	Omicron
Preconception	21	Preconception	195	M	Omicron
2 ^o	21	2 ^o	96	A	Omicron
Preconception*	-	-	354	A	Omicron
2 ^o	21	2 ^o	103	A	Omicron
1 ^o	21	1 ^o	195	A	Omicron

Supplementary Table S1: Temporal trends in COVID-19 vaccine in our 27 vaccinated women. Description of vaccination received by study subjects, the number of doses, the interval between dose, and timing between last dose and SARS-CoV-2 diagnosis. SYN, symptoms of SARS-CoV-2 infection; S, severe; M, mild; A, asymptomatic. PS, Predominant strain (in Aragón) at the moment of SARS-CoV-2 diagnosis. All subjects received mRNA-based vaccines except for study subjects marked*, who received Viral vector-based vaccines. Only the subject marked # received a third dose: 290 days after the first dose, during the 2^o trimester of pregnancy mRNA.